英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
vipers查看　vipers　在百度字典中的解释百度英翻中〔查看〕
vipers查看　vipers　在Google字典中的解释Google英翻中〔查看〕
vipers查看　vipers　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Larimar Therapeutics
    Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases The company’s lead product candidate, nomlabofusp (previously known as CTI-1601), is currently being evaluated in a Phase 2 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive
  • Press Releases - Larimar Therapeutics, Inc.
    BALA CYNWYD, Pa , March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in
  • News – Larimar Therapeutics
    May 14, 2026 Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update > Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 Cross-species nonclinical findings that support skin frataxin levels as a April 30
  • Careers – Larimar Therapeutics
    Careers Be part of the Larimar team! Larimar is a dynamic company seeking to develop treatments that improve the lives of patients with rare diseases We are collaborative, creative and rigorous in our approaches The company is located in the greater Philadelphia area
  • Pipeline – Larimar Therapeutics
    Pipeline Larimar’s lead compound, nomlabofusp, is currently being evaluated in a Phase 2 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease The company also plans to use its proprietary protein replacement therapy platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular
  • Leadership – Larimar Therapeutics
    Maha Saad, PhD, MBA > Vice President, Pharmacovigilance (PV) and Product Safety
  • Larimar Therapeutics, Inc.
    Larimar Therapeutics, Inc
  • Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for . . .
    Larimar Therapeutics, Inc (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia
  • Larimar Therapeutics Announces Positive Data from Ongoing Long-term . . .
    BALA CYNWYD, Pa , Sept 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of
  • Nomlabofusp – Larimar Therapeutics
    Larimar’s nomlabofusp development program was also selected by the FDA to participate in its START (Support for clinical Trials Advancing Rare disease Therapeutics) pilot program, which is designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases About Friedreich’s Ataxia (FA)





中文字典-英文字典  2005-2009